Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.

PMID:
29899021
2.

Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity.

Peters TL, Tillotson J, Yeomans AM, Wilmore S, Lemm E, Jiménez-Romero C, Amador LA, Li L, Amin AD, Pongtornpipat P, Zerio CJ, Ambrose AJ, Paine-Murrieta G, Greninger P, Vega F, Benes CH, Packham G, Rodríguez AD, Chapman E, Schatz JH.

Clin Cancer Res. 2018 Sep 1;24(17):4256-4270. doi: 10.1158/1078-0432.CCR-17-3645. Epub 2018 May 29.

PMID:
29844128
3.

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.

Puvvada SD, Guillén-Rodríguez JM, Yan J, Inclán L, Heard K, Rivera XI, Anwer F, Mahadevan D, Schatz JH, Persky DO.

Oncology. 2018;94(5):274-280. doi: 10.1159/000486788. Epub 2018 Feb 22.

PMID:
29471300
4.

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.

Puvvada SD, Guillen-Rodriguez J, Kumar A, Inclán L, Heard K, Rivera XI, Anwer F, Schatz JH, Mahadevan D, Persky DO.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):58-64. doi: 10.1016/j.clml.2017.09.001. Epub 2017 Sep 19.

PMID:
29056470
5.

A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma.

Puvvada SD, Guillén-Rodríguez JM, Rivera XI, Heard K, Inclan L, Schmelz M, Schatz JH, Persky DO.

Oncology. 2017;93(6):401-405. doi: 10.1159/000479230. Epub 2017 Sep 5.

PMID:
28869931
6.

ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.

Tillotson J, Kedzior M, Guimarães L, Ross AB, Peters TL, Ambrose AJ, Schmidlin CJ, Zhang DD, Costa-Lotufo LV, Rodríguez AD, Schatz JH, Chapman E.

Bioorg Med Chem Lett. 2017 Sep 1;27(17):4082-4085. doi: 10.1016/j.bmcl.2017.07.045. Epub 2017 Jul 19.

7.

Double hit lymphoma presenting as haemophagocytic lymphohistiocytosis.

Rivera XI, McGhan LJ, Schatz JH, Puvvada SD.

BMJ Case Rep. 2017 May 15;2017. pii: bcr-2017-220401. doi: 10.1136/bcr-2017-220401. No abstract available.

PMID:
28512105
8.

Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?

Amin AD, Peters TL, Li L, Rajan SS, Choudhari R, Puvvada SD, Schatz JH.

Cold Spring Harb Mol Case Stud. 2017 May;3(3):a001719. doi: 10.1101/mcs.a001719. Review.

9.

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.

Peters TL, Li L, Tula-Sanchez AA, Pongtornpipat P, Schatz JH.

Oncotarget. 2016 Sep 27;7(39):63362-63373. doi: 10.18632/oncotarget.11457.

10.

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

Amin AD, Li L, Rajan SS, Gokhale V, Groysman MJ, Pongtornpipat P, Tapia EO, Wang M, Schatz JH.

Oncotarget. 2016 Apr 26;7(17):23715-29. doi: 10.18632/oncotarget.8173.

11.

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.

Amin AD, Rajan SS, Groysman MJ, Pongtornpipat P, Schatz JH.

Biomark Cancer. 2015 Dec 15;7(Suppl 2):25-32. doi: 10.4137/BIC.S29326. eCollection 2015. Review.

12.

Kinase overexpressing cancers responsive to drug withdrawal.

Amin AD, Rajan SS, Schatz JH.

Aging (Albany NY). 2015 Oct;7(10):752-3. No abstract available.

13.

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

Amin AD, Rajan SS, Liang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, Schatz JH.

Cancer Res. 2015 Jul 15;75(14):2916-27. doi: 10.1158/0008-5472.CAN-14-3437. Epub 2015 May 27.

14.

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.

Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH.

Leukemia. 2015 Aug;29(8):1702-12. doi: 10.1038/leu.2015.99. Epub 2015 Apr 17.

15.

A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature.

Taverna J, Nair A, Yun S, Paulson S, Schatz JH, Persky D, Fuchs D, Puvvada S.

Case Rep Hematol. 2014;2014:145129. doi: 10.1155/2014/145129. Epub 2014 Nov 16.

16.

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.

Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, Socci ND, Lailler N, Heguy A, Dolgalev I, Migliacci JC, Pirun M, Palomba ML, Weinstock DM, Wendel HG.

Leukemia. 2015 Jan;29(1):237-41. doi: 10.1038/leu.2014.261. Epub 2014 Sep 3. No abstract available.

17.

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.

Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Rätsch G, Wendel HG.

Nature. 2014 Sep 4;513(7516):65-70. doi: 10.1038/nature13485. Epub 2014 Jul 27.

18.

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.

Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, McKeithan T, Sander C, Tam W, Seshan VE, Chan WC, Chaganti RS, Wendel HG.

J Exp Med. 2014 Jun 30;211(7):1379-91. doi: 10.1084/jem.20132120. Epub 2014 Jun 9.

19.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM.

Blood. 2014 Feb 27;123(9):1293-6. doi: 10.1182/blood-2013-10-531509. Epub 2013 Dec 17.

20.

Progress against follicular lymphoma.

Schatz JH, Oricchio E, Puvvada SD, Wendel HG.

Curr Opin Hematol. 2013 Jul;20(4):320-6. doi: 10.1097/MOH.0b013e3283622ed6. Review.

21.

Targeted cancer therapy: what if the driver is just a messenger?

Schatz JH, Wendel HG.

Cell Cycle. 2011 Nov 15;10(22):3830-3. doi: 10.4161/cc.10.22.18288. Epub 2011 Nov 15.

22.

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.

Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS, Wendel HG.

Cell. 2011 Oct 28;147(3):554-64. doi: 10.1016/j.cell.2011.09.035.

23.

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.

Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, Porco JA Jr, Teruya-Feldstein J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG.

J Exp Med. 2011 Aug 29;208(9):1799-807. doi: 10.1084/jem.20110846. Epub 2011 Aug 22.

24.

Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.

Schatz JH.

Curr Oncol Rep. 2011 Oct;13(5):398-406. doi: 10.1007/s11912-011-0187-7.

PMID:
21755275
25.

Mouse models of cancer as biological filters for complex genomic data.

Oricchio E, Wolfe AL, Schatz JH, Mavrakis KJ, Wendel HG.

Dis Model Mech. 2010 Nov-Dec;3(11-12):701-4. doi: 10.1242/dmm.006296. Epub 2010 Sep 27.

26.

Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.

Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R.

Blood. 2010 Oct 14;116(15):2759-67. doi: 10.1182/blood-2009-07-234559. Epub 2010 Jun 28.

27.

Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant.

Jhaveri KD, Schatz JH, Young JW, Flombaum C.

Transplantation. 2008 Jul 15;86(1):180-1. doi: 10.1097/TP.0b013e31817baa80. No abstract available.

PMID:
18622299
28.

Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation.

Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H.

Immunity. 2006 Aug;25(2):225-36.

Supplemental Content

Loading ...
Support Center